Dogwood Therapeutics, Inc. (DWTX) 10-Year Financial Performance & Capital Metrics

DWTX • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

AboutDogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.Show more

Revenue $0
EBITDA -$12M -124.3%
Net Income -$12M -133.2%
EPS (Diluted) -12.52 -77.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -36.28% +61.9%
ROIC -28% +97.3%
Debt/Equity 0.24
Interest Coverage -132.63

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Shares diluted 36.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-567.33%

EPS CAGR

10Y-

5Y-

3Y-

TTM-288.91%

ROCE

10Y Avg-75.34%

5Y Avg-75.34%

3Y Avg-78.82%

Latest-25.76%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-
Operating Expenses+	1.96M	2.18M	10.01M	15.64M	12.32M	5.45M	12.23M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	1.11M	1.38M	9.81M	4.85M	4.25M	3.72M	8.7M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	854.11K	800.62K	194.01K	10.8M	8.07M	1.73M	3.53M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income+	-1.96M	-2.18M	-10.01M	-15.64M	-12.32M	-5.45M	-12.23M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.11%	-3.59%	-0.56%	0.21%	0.56%	-1.24%
EBITDA+	-1.96M	-2.18M	-10.01M	-15.64M	-12.32M	-5.45M	-12.22M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.11%	-3.59%	-0.56%	0.21%	0.56%	-1.24%
D&A (Non-Cash Add-back)	0	0	0	0	0	0	12.18K
EBIT	-1.96M	-2.18M	-10.01M	-15.64M	-12.32M	-5.45M	-12.26M
Net Interest Income+	-152.1K	-295.13K	-384.22K	5.67K	67.47K	150.9K	-92.19K
Interest Income	0	0	0	5.67K	67.47K	150.9K	0
Interest Expense	152.1K	295.13K	384.22K	0	0	0	92.19K
Other Income/Expense	-152.1K	-295.13K	-341K	-319.33K	67.47K	150.9K	-122.98K
Pretax Income+	-2.11M	-2.47M	-10.35M	-15.96M	-12.25M	-5.3M	-12.35M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	-503
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-2.11M	-2.47M	-10.35M	-15.96M	-12.25M	-5.3M	-12.35M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-0.17%	-3.18%	-0.54%	0.23%	0.57%	-1.33%
Net Income (Continuing)	-2.11M	-2.47M	-10.35M	-15.96M	-12.25M	-5.3M	-12.35M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-10.93	-12.80	-52.50	-47.90	-27.66	-7.05	-12.52
EPS Growth %	-	-0.17%	-3.1%	0.09%	0.42%	0.75%	-0.78%
EPS (Basic)	-10.93	-12.80	-52.50	-47.90	-27.66	-7.05	-12.52
Diluted Shares Outstanding	193.3K	193.3K	197.08K	333.17K	442.8K	751.07K	1.03M
Basic Shares Outstanding	193.3K	193.3K	197.08K	333.17K	442.8K	751.07K	1.03M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	42.4K	315.9K	31.47M	15.78M	8.37M	4.17M	16.54M
Cash & Short-Term Investments	30.03K	309.38K	29.8M	14.01M	7.03M	3.32M	14.85M
Cash Only	30.03K	309.38K	29.8M	14.01M	7.03M	3.32M	14.85M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	334	785	324	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	0	863	7.29K	3.56K	28.01K
Total Non-Current Assets+	23.54K	0	0	0	0	0	77.76M
Property, Plant & Equipment	0	0	0	0	0	0	222.65K
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	11.81M
Intangible Assets	0	0	0	0	0	0	65.71M
Long-Term Investments	0	0	0	0	0	0	18.13K
Other Non-Current Assets	23.54K	0	0	0	0	0	0
Total Assets+	65.94K	315.9K	31.47M	15.78M	8.37M	4.17M	94.31M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	3.79%	98.63%	-0.5%	-0.47%	-0.5%	21.64%
Total Current Liabilities+	1.33M	1.62M	1.53M	1.28M	1.04M	358.55K	3.18M
Accounts Payable	145.66K	35.42K	368.9K	353.86K	573.16K	111.91K	1.23M
Days Payables Outstanding	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	49.7K
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	0	0	573.48K	532.68K	159.7K	0	687.59K
Current Ratio	0.03x	0.19x	20.55x	12.37x	8.02x	11.62x	5.21x
Quick Ratio	0.03x	0.19x	20.55x	12.37x	8.02x	11.62x	5.21x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	3.64M	0	0	0	0	26.85M
Long-Term Debt	0	3.64M	0	0	0	0	15.38M
Capital Lease Obligations	0	0	0	0	0	0	154.88K
Deferred Tax Liabilities	0	0	0	0	0	0	11.31M
Other Non-Current Liabilities	0	0	0	0	0	0	0
Total Liabilities	1.33M	5.26M	1.53M	1.28M	1.04M	358.55K	30.03M
Total Debt+	0	3.64M	0	0	0	0	15.59M
Net Debt	-30.03K	3.33M	-29.8M	-14.01M	-7.03M	-3.32M	737.71K
Debt / Equity	-	-	-	-	-	-	0.24x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-12.90x	-7.38x	-26.04x	-	-	-	-132.63x
Total Equity+	-1.26M	-4.94M	29.94M	14.5M	7.33M	3.81M	64.28M
Equity Growth %	-	-2.92%	7.06%	-0.52%	-0.49%	-0.48%	15.89%
Book Value per Share	-6.52	-25.57	151.92	43.52	16.55	5.07	62.54
Total Shareholders' Equity	-1.26M	-4.94M	29.94M	14.5M	7.33M	3.81M	64.28M
Common Stock	12.6M	12.6M	830	833	1.83K	77	133
Retained Earnings	-15.15M	-17.62M	-27.97M	-43.93M	-56.17M	-61.47M	-73.82M
Treasury Stock	0	0	0	0	0	-299.13K	-299.13K
Accumulated OCI	0	0	0	0	0	0	-3.86M
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.2M	-2.09M	-3.9M	-15.69M	-11.47M	-4.87M	-8.79M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.75%	-0.86%	-3.03%	0.27%	0.58%	-0.8%
Net Income	-2.11M	-2.47M	-10.35M	-15.96M	-12.25M	-5.3M	-12.35M
Depreciation & Amortization	0	0	0	0	0	0	12.18K
Stock-Based Compensation	0	0	7.43M	322.88K	582.66K	619.97K	476.02K
Deferred Taxes	0	0	0	0	0	0	-503
Other Non-Cash Items	48.51K	65K	-4.26K	0	0	0	3.65M
Working Capital Changes	869.13K	316.48K	-974.06K	-52.19K	197.38K	-194.45K	-581.27K
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	65.64K	-89.82K	51.56K	270.01K	219.3K	-461.25K	219.89K
Cash from Investing+	0	0	0	0	0	0	3.76M
Capital Expenditures	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0
Cash from Financing+	1.15M	2.37M	33.38M	-97.6K	4.49M	1.16M	16.7M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	-75K	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	-69.53K	-58.49K	112.99K	197.56K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-1.2M	-2.09M	-3.9M	-15.69M	-11.47M	-4.87M	-8.79M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	-0.75%	-0.86%	-3.03%	0.27%	0.58%	-0.8%
FCF per Share	-6.19	-10.82	-19.76	-47.09	-25.90	-6.48	-8.55
FCF Conversion (FCF/Net Income)	0.57x	0.85x	0.38x	0.98x	0.94x	0.92x	0.71x
Interest Paid	0	0	12.55K	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-82.78%	-71.83%	-112.22%	-95.14%	-36.28%
Return on Invested Capital (ROIC)	-	-	-	-3675.02%	-2343.15%	-1040.22%	-28%
Debt / Equity	-	-	-	-	-	-	0.24x
Interest Coverage	-12.90x	-7.38x	-26.04x	-	-	-	-132.63x
FCF Conversion	0.57x	0.85x	0.38x	0.98x	0.94x	0.92x	0.71x

Frequently Asked Questions

Growth & Financials

Dogwood Therapeutics, Inc. (DWTX) grew revenue by 0.0% over the past year. Growth has been modest.

Dogwood Therapeutics, Inc. (DWTX) reported a net loss of $38.2M for fiscal year 2024.

Dividend & Returns

Dogwood Therapeutics, Inc. (DWTX) has a return on equity (ROE) of -36.3%. Negative ROE indicates the company is unprofitable.

Dogwood Therapeutics, Inc. (DWTX) had negative free cash flow of $18.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener